BlackRock, Inc. 13D and 13G filings for Kymera Therapeutics, Inc.:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company's equity securities.
- Shares have been adjusted for stock splits.
| Reported DateTime |
Transaction Date |
Type | Company Symbol |
Filed By Symbol |
Shares Owned % Owned |
Shares Vs. Prev Report | View |
| 2024-01-29 3:26 pm Purchase |
2023-12-31 | 13G | Kymera Therapeutics, Inc. KYMR |
BlackRock Inc. BLK |
3,566,611 6.400% |
231,710 (+6.95%) |
Filing |
| 2023-02-01 4:54 pm Sale |
2022-12-31 | 13G | Kymera Therapeutics, Inc. KYMR |
BlackRock Inc. BLK |
3,334,901 6.100% |
-62,639 (-1.84%) |
Filing |
| 2022-02-04 4:12 pm Purchase |
2021-12-31 | 13G | Kymera Therapeutics, Inc. KYMR |
BlackRock Inc. BLK |
3,397,540 6.600% |
3,397,540 (New Position) |
Filing |